Clinical Trial Update: A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia [Phase 3]

View source ↗

Summary

Phase 3 trial comparing co-administered HGP0608, HGP0904 and HCP1306 versus HCP1701 in hypertension and dyslipidemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemias
• Hypertension

Drugs mentioned

• HCP1306
• HCP1701
• HGP0608
• HGP0904

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: Hypertension, Dyslipidemias | Phase 3 | Status: COMPLETED